Buy & Sell Boston Scientific Corporation (BSX) – Boston Scientific Corporation Price Today
Aura AI Summary
Key Stats
- $66.81BMarket Cap
- HealthSector
- -35.94%3M Drawdown
- $76.39BEnterprise Value
- -Dividend Yield
- 33% Buy | 67% SellTrading Activity
- 71 daysTypical Hold Time
Boston Scientific Corporation (BSX) is currently valued at a market capitalization of $66.81B, with an enterprise value of $76.39B. Over the past 52 weeks, Boston Scientific Corporation has traded between a low of $44.95 and a high of $108.14, highlighting its annual price range. Over the past three months, Boston Scientific Corporation has recorded a drawdown of -35.94%, reflecting recent price volatility. On average, investors hold Boston Scientific Corporation for approximately 71 days, indicating typical investor behavior on the platform.
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Most Recent News
Carnival shares rise as US-Iran peace deal lowers oil prices, boosting cruise margins.
Carnival Corporation's stock surged following a US-Iran memorandum of understanding to end hostilities and reopen the Strait of Hormuz, allowing Iranian oil exports to resume. This deal led to a drop in oil prices, with West Texas Intermediate fallin...

Covista CEO sells 5,300 shares near 8-month high stock price
Covista's Chairman and CEO sold about 5,300 shares recently when the stock price was near its highest level in eight months. This insider sale could indicate the CEO is taking profits after a strong run in the stock. Investors might watch for further...

Investigation launched into Gildan Activewear over alleged revenue inflation and financial engineering.
Bronstein, Gewirtz & Grossman, LLC has opened an investigation into Gildan Activewear following a report accusing the company of inflating revenues by channel stuffing and obscuring financial details through off-balance sheet receivables. The report ...
